TG Therapeutics (NASDAQ:TGTX – Get Free Report) and Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.
Profitability
This table compares TG Therapeutics and Xenon Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TG Therapeutics | 13.31% | 26.05% | 9.58% |
| Xenon Pharmaceuticals | N/A | -38.50% | -36.47% |
Risk and Volatility
TG Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TG Therapeutics | 0 | 2 | 2 | 1 | 2.80 |
| Xenon Pharmaceuticals | 1 | 0 | 11 | 1 | 2.92 |
TG Therapeutics presently has a consensus price target of $50.25, suggesting a potential upside of 55.86%. Xenon Pharmaceuticals has a consensus price target of $53.70, suggesting a potential upside of 40.39%. Given TG Therapeutics’ higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Xenon Pharmaceuticals.
Institutional and Insider Ownership
58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares TG Therapeutics and Xenon Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TG Therapeutics | $531.90 million | 9.62 | $23.38 million | $2.78 | 11.60 |
| Xenon Pharmaceuticals | $7.50 million | 393.24 | -$234.33 million | ($3.89) | -9.83 |
TG Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
TG Therapeutics beats Xenon Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
